Targeting SPINK 1–EGFR interactions with neutralizing antibodies or tyrosine kinase inhibitors could effectively suppress tumor growth in cancers where SPINK 1 is a known driver, such as pancreatic and PC (Table 3). Here, EGFR is linked to cancer.